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Abstract
Health issue: Although lung cancer is the leading cause of cancer deaths for Canadian women,
breast cancer is the most frequently diagnosed. About 5400 women are expected to die from this
disease in 2003. In 1998, a woman's lifetime risk of breast cancer was about one in nine.
Key findings: A number of risk factors for breast cancer have been identified. These include
advancing age, hormonal factors (eg. early menarche, late menopause and late age at first full-term
pregnancy), familial risk, BRCA-1 and BRCA-2 gene mutations, diet and postmenopausal obesity.
Several interventions have been introduced to assist women at high risk for breast cancer, including
genetic counseling and testing for women who have strong family histories of breast cancer;
selective estrogen receptor modifiers, such as tamoxifen, that has been shown to reduce breast
cancer rates; prophylactic mastectomy and screening.
Data gaps and recommendations: Guidelines are unclear in several areas, particularly in
screening. Where clinical guidelines are available, health services research or ongoing monitoring
(by provincial/territorial cancer agencies) is needed to assess compliance with the guidelines and to
ensure equity of access within the provinces/territories.
Key components of organized screening programs need to be established, in part to ensure that 
screening is carried out in high-quality, co-ordinated programs. There is also a need to develop 
ways to involve women fully in informed decision-making and to address several policy issues to 
prevent disparities in access to high-quality services. Patenting issues associated with genetic tests 
also need to be clarified.
Background
The last decade has seen breast cancer come to the fore-
ground as one of the chief health concerns of Canadian
women, partly because of the importance of breast cancer
as a cause of illness and premature mortality, and also as
a result of the work of advocacy groups in bringing this
issue to public attention. In 1992, a House of Commons
Standing Committee report, Breast Cancer: Unanswered
Questions, identified a number of issues in breast cancer
research, prevention and care. This resulted in a National
Forum on Breast Cancer, a major strategic event spon-
sored by the Canadian Cancer Society, the National Can-
cer Institute of Canada, the Medical Research Council and
Health Canada, held in Montréal in 1993. [1] The legacy
of this forum was a coordinated strategy in breast cancer,
which has been developed over the past 10 years.
This chapter will provide data on the impact of breast can-
cer in epidemiologic terms, the progress that has been
made in preventing the disease, and the questions – either
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research- or policy-based – that continue to present them-
selves to us.
Methods
This is in large part a review of available literature at the
time of publication. Specific data are cited in the Figures,
and the methods for their production are listed in the
source documents. The work of Health Canada, the
National Cancer Institute of Canada and the Alberta Can-
cer Board is acknowledged in the production of these
Figures.
Results
Epidemiology in Canada
Breast cancer is the most common invasive cancer among
Canadian women. [2] Age-standardized breast cancer
incidence rates increased by 25% among Canadian
women between 1973 and 1998, [2] as shown in Figure 1.
It appears that much of the increase was in the earlier years
of this period. The cause of the increase is not well under-
stood, although some have suggested that changes in
reproductive patterns could be partially responsible. [3]
There is also speculation that some of the increase in the
late 1980s and early 1990s could have been due to addi-
tional detections arising as a result of screening mammog-
raphy. [4] However, the rates appear to have levelled off
since 1993, despite increased use of mammography in the
1990s. [5] Some of this levelling off may have been
expected: screening causes an increase in detection in the
year of its introduction and, as a result, a decrease in breast
cancers found in subsequent years. The degree to which
this or other factors may be operating is not well under-
stood and bears further surveillance.
Most women are aware of the lifetime risk of breast cancer
as being close to 1 in 10; in 1998, the risk was about
11.4% or 1 in 9. [2] This is highly age-dependent, how-
ever. Risk over the next 10-year period may be a more rea-
sonable number for women and physicians to use to
estimate risk, [6] and this increases with age (Figure 2).
The risk falls only after the age of 80, probably because
other causes of death remove the woman from risk for
part of the time.
The news about mortality is somewhat better – the age-
standardized mortality rate has fallen by about 15% since
1973, with most of the improvement since 1990. [2]
However, breast cancer remains a major contributor to
mortality in Canada, and about 5,400 women are
expected to die from the disease in 2003. Although breast
cancer was the leading cause both of cancer deaths and of
potential years of life lost (PYLL) for all causes in the early
part of the last decade, [7] it has now been overtaken by
lung cancer on both measures. [2] Nevertheless, breast
cancer accounts for 94,000 PYLL in Canada, or 6.7% of all
premature mortality years for Canadian women.
The reduction in mortality rates has not resulted from a
decrease in the number of cases of breast cancer and must
therefore reflect better survival in those affected. There is
evidence that this is the case. Data from Alberta indicate
temporal trends towards improved 10-year survival [8]
(Figure 3). However, even with this evidence it is difficult
to know whether the improvements are due to screening
(finding cancers at an earlier, more treatable stage) or to
better treatment for some or all stages of cancer. [9]
Age Standardized Incidence and Mortality Rates for Females,  Canada, 1974–1999 Figure 1
Age Standardized Incidence and Mortality Rates for 
Females, Canada, 1974–1999 Source: National Cancer 
Institute of Canada. Canadian Cancer Statistics 2003. 
Toronto, Canada, 2003
Probability of Developing Breast Cancer by Age Figure 2
Probability of Developing Breast Cancer by Age 
Source: National Cancer Institute of Canada. Canadian Can-
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Provincial/Territorial Variations
Within Canada, the estimated 2002 mortality rates vary
from a low of 22 deaths per 100,000 women inSaskatch-
ewan (age-standardized to the 1991 Canadian popula-
tion) to 29 in Nova Scotia and Newfoundland and
Labrador. [2] There are similar variations in age-standard-
ized five-year relative survival rates (1992 diagnosis year),
from a low of 76% in Newfoundland and Labrador to a
high of 85%in British Columbia. [10] It has been sug-
gested that the latter variations may reflect differences in
mammography utilization across the country. [10]
Ethnic Groups
Little is known in Canada about differences in cancer inci-
dence or mortality across different ethnic or racial groups,
as Canadian cancer registries do not collect this informa-
tion. There is a suggestion that rates are lower in Inuit
populations, although there was a trend to an increase in
the 1969–1973 and the 1984–1988 periods. [11] Further
research and/or enhanced surveillance is needed to
determine the impact of cancer on Aboriginal and immi-
grant populations in Canada.
International Data
Worldwide, there seems to be some movement towards
convergence of breast cancer mortality rates. Rates are
higher in North America and northern Europe than in less
industrialized and Asian nations. [12] However, rates are
declining in industrialized countries such as the United
Kingdom, United States, Germany and Canada, and
increasing in Japan. These differences seem to have envi-
ronmental (as opposed to genetic) causes, as migrants
from low-risk countries to Canada and Australia tend to
acquire higher rates of risk. [13] Recent U.S. analyses
point to a decrease in mortality among women born after
1948, although the reasons for this are not well under-
stood. [14]
Risk Factors for Breast Cancer
The strongest risk factors for female breast cancer – those
that raise the individual's risk at least fourfold – include
age and country of birth, both described earlier. [15]
Familial factors are also important, although to reach this
high level of risk an individual would have to have both a
mother and a sister with breast cancer. Mutations in the
BCRA1 or BCRA2 genes also confer high risk, and these
will be discussed later. The other factor to reach this risk
level is the presence of atypical epithelial cells in nipple
aspirate fluid, although the test that detects the cells is
generally used only in research contexts.
Hormonal Factors
Reproductive and hormonal factors have long been linked
to breast cancer risk. The well-known factors include early
age at menarche and late age at menopause, or a late age
at the first full-term pregnancy. Nulliparity, or never com-
pleting a full-term pregnancy, increases the risk of breast
cancer after age 40 (the vast majority of breast cancers
occur after this age), although pregnancy may confer an
increased risk of cancer before the age of 40. [15] These
risk factors are all relatively weak on an individual basis,
conferring arelative risk of less than double for women
with these characteristics compared to women without
these characteristics.
Hormone therapy (HT) has been a controversial area in
the breast cancer literature. Before publication of the
randomized controlled trial known as the Women's
Health Initiative (WHI) study in 2002, large pooled anal-
yses of observational studies showed an increase in breast
cancer risk among women undergoing HT, which
appeared to increase with duration of use. [16] It was
thought, however, that this increased risk could be out-
weighed by potential cardiovascular benefits. The WHI
study confirmed an increase in breast cancer risk of about
26% over 5.2 years [17] with combined estrogen/proges-
tin therapy. Although this was a concern, the major find-
ing of the study was the reporting of an increase, rather
than the expected decrease, in coronary heart disease.
While this may, in part, have been due to the age of the
women at the time of study enrolment, it was felt that the
overall hazard ratio for the drug was unacceptable, and
this portion of the study was discontinued (the estrogen-
only trial is still under way). Many organizations are now
recommending combined HT only for relief of symptoms
at the time of menopause, and Health Canada discourages
its long-term use except in limited circumstances. [18]
Breast Cancer Survival Between 1985 and 1996 Figure 3
Breast Cancer Survival Between 1985 and 1996 
Source: Alberta Cancer Board, A Snapshot of Cancer in 
Alberta 2001. Calgary, Alberta.BMC Women's Health 2004, 4:S12 http://www.biomedcentral.com/1472-6874/4/S1/S12
Page 4 of 8
(page number not for citation purposes)
Diet and Obesity
Because of the worldwide variations in breast cancer inci-
dence, there have been many studies attempting to link
risk to variations in diet. Despite many years of study,
there is little conclusive evidence on dietary fat or other
putative dietary risk factors.
Post-menopausal obesity increases risk to some degree. If
population trends in obesity continue, [19] this may
cause a gradual increase in rates in years to come. Physical
activity appears to be protective for breast cancer risk, even
if activity begins after menopause. [20] Alcohol has been
suggested as a risk factor in most studies, [21] and some
cohort studies have shown about a 30% increased risk of
breast cancer among drinkers. [22,23] However, a moder-
ate use of alcohol is preventive for other diseases, such as
diabetes mellitus, so the public health recommendations
that should be derived from this are unclear.
Radiation
Exposure to high levels of ionizing radiation, especially at
a young age, is an acknowledged, if somewhat rare, risk
factor. [15] The levels known to increase risk are high, and
often these types of exposures have already fallen out of
favour or have been severely restricted (e.g. use of fluoros-
copy in tuberculosis, radiation treatments for acne or
thymic enlargement, etc.).
Familial and Genetic Risk
A family history of breast cancer is perhaps the best-
known risk factor. Recent pooling of data from 52 epide-
miologic studies indicates that women with no affected
first-degree relatives (mother, sister ordaughter) have a
7.8% probability of developing breast cancer by age 80,
whereas those with a historyof breast cancer in one first-
degree relative have a risk of 13.3%; [24] the risk increases
to 21.1% for those with two first-degree relatives. How-
ever, less than 1% of women with breast cancer actually
have a family history this strong. In fact, eight out of nine
women with breast cancer do not have an affected first-
degree relative, and the vast majority of those with a fam-
ily history will not develop breast cancer themselves. [24]
Despite this, there is a small group of women whose
familial histories and/or genetic profiles put them at a
considerably increased risk. The best-known susceptibility
genes, BCRA1 and BCRA2, are believed to have a com-
bined population frequency of about 1.2 per 1,000
women. [25] About 35% of women with a BCRA1 gene
defect and 50% of those with a BCRA2 defect would be
expected to develop breast cancer by the age of 70. [25]
These women also have an increased risk of ovarian can-
cer, which would be considered in any counselling or sur-
veillance strategies.
Interventions
Genetic Testing
Women who have strong family histories with more than
one first-degree relative affected, especially with early-age
onset, may be considered for genetic counselling and
potentially for familial genetic testing. Women with fam-
ily histories often overestimate their degree of risk, [26]
and counselling helps to put the risks and benefits of such
testing in perspective. Women need to understand that
not all strong family histories can be linked to single gene
defects, and so there is a possibility that such testing will
be inconclusive in some families.
Further, the steps to be taken if a genetic defect is found
are not entirely clear. Although some would recommend
increased mammographic screening, others suggest that
women with breast cancer susceptibility genes may actu-
ally be more sensitive to radiation, and thus they question
the wisdom of this strategy. [27]
At the time of writing, a controversy exists that may limit
the availability of genetic testing for Canadian women.
[28] Some governments, including several in Europe, are
challenging the granting of patents forhuman genes. [29]
There will need to be considerably more debate on genetic
patenting, both in Canada and worldwide.
Selective Estrogen Receptor Modifiers
Some studies are now addressing potential interventional
strategies to lower breast cancer risk among women whose
current risk is quite high. Tamoxifen is one of a class of
drugs known as SERMs, or selective estrogen receptor
modifiers. This drug has been shown to reduce breast can-
cer rates (as well as fractures, as a result of its prevention
of osteoporosis) among women whose family history and
other risk factors place them at elevated risk. [30] How-
ever, there were not enough women with known BCRA1
and BCRA2 defects in this study to make confident con-
clusions about its use in this group of women. [31] Math-
ematical models predict that the benefit would be modest,
however, with about a 13% to 27% reduction of risk at
current estimates. [32]
Unfortunately, tamoxifen has also been associated with
increased risk of endometrial cancer and thrombotic
(blood clotting) events. This has led to new trials with
another SERM, raloxifene. The results of a study designed
to look at the effect of raloxifene on osteoporosis preven-
tion showed promising results in breast cancer reduction
[33] with little effect on uterine cancer rates. The STAR
(Study of Tamoxifen and Raloxifene) trial is now in
progress to compare tamoxifen and raloxifene. [34]BMC Women's Health 2004, 4:S12 http://www.biomedcentral.com/1472-6874/4/S1/S12
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Mastectomy
The other interventional strategy that could be considered
to lower breast cancer incidence in cases of very high risk
is prophylactic mastectomy. This has been found to
reduce breast cancer risk by about 90%, [35] although
occasional cases of breast cancer still occur. Clearly,
women need detailed information on the potential risks
and benefits of either the surgical or medical preventive
strategies.
Screening
For well over a decade, Canadian women have been
advised that breast screening includes three components:
breast self-examination (BSE), clinical breast examination
(CBE) and, for some age groups, mammography.
Mammography
A report of an international workshop held by the
National Cancer Institute (NCI) in 1993 was one of the
most influential statements over much of the last decade
[36]. This report found that routine mammographic
screening for women aged 50 to 69 reduced breast cancer
by about a third. However, it noted that for women aged
40 to 49, there was no benefit at 5 to 7 years of screening,
and the benefit at 12 years of follow-up, if present at all,
was marginal. [36] Another consensus panel, convened in
1997, still found insufficient evidence to recommend rou-
tine screening for women in their 40s. [37] Despite this,
the NCI chose to make recommendations for routine
mammography in this age group. [38] The Canadian Pre-
ventive Services Task Force reviewed the issue in 2001 and
did not find sufficient evidence to recommend mammo-
graphic screening in this age group. [39]
Because women in their 40s must come to some kind of a
decision in the face of conflicting recommendations, it is
important to provide them with information that will
help them make a decision with which they are comforta-
ble. Any screening test involves some risk, as there is
always the possibility that a false positive test will result in
unnecessary, invasive tests, or that a false negative test will
inappropriately reassure a woman when a cancer is
present. For women in their 40s, the risk of a false positive
test over a decade of biennial screening is estimated to be
about 30%, and for 10 screening mammograms in this
period about 56%. [40] The sensitivity of mammography
is lower before menopause (about 78% versus 90%
among women over 50). [41] Thus, there is a risk of hav-
ing to undergo additional tests because of false positive
screens, and there is also about one chance in four that a
cancer that is present will not be detected. On the other
hand, there may be a small reduction in breast cancer
mortality after several years of follow-up. Decision aids
that would help women weigh this information and make
a personal decision are needed.
For the past year, the debate has taken on another form,
however. A reanalysis published in the Lancet in 2001
suggested that mammography was not beneficial in any
age group. [42] Because of the controversy generated, the
U.S. Preventive Health Services Task Force, the National
Cancer Institute and the World Health Organization
reviewed their recommendations and, as a result, con-
firmed the benefits of screening mammography. [43-45]
Breast Self-Examination
Another screening procedure, BSE, has also been revisited
in the past couple of years. A recent update found that
there is no evidence of benefit and some evidence of risk,
and so recommended that it not be routinely advised. [46]
This again caused controversy, as many women felt that it
was the only procedure available to them before the age of
routine mammography or between mammography visits.
For those women who actively decide to do BSE after a
discussion of risks and potential benefits, consideration
can still be given to providing high-quality teaching
resources so that the procedure is as beneficial as possible.
Organized Screening Programs
As early as 1989, there were recommendations in Canada
that mammographic screening be done in the context of
organized screening programs, [47] a suggestion that was
reiterated at the National Forum on Breast Cancer in
1993, [1] when the elements necessary for high-quality
screening of the target population were spelled out:
• a population-based outcome goal
• information about the target population
• attention to those hard to reach
• meticulous quality assurance, including equipment and
interpretation
• outcome data and analysis
• a woman-centred focus
• information systems and linkages
• coordination with high-quality diagnosis
Between 1988 and 1991, five provinces and one territory
inaugurated programs; they are now in place in all 10
provinces and in 2 territories. [48] There has been evi-
dence that provinces and territories that initiated pro-
grammatic screening early were more effective in reaching
the target population. [49] The programs report on their
outcomes nationally and show a high degree ofBMC Women's Health 2004, 4:S12 http://www.biomedcentral.com/1472-6874/4/S1/S12
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compliance with international standards for cancer detec-
tion rates, referral rates and other quality indicators. [48]
One of the quality determinants for screening is a recom-
mended minimum number of readings of3,000 films per
radiologist per year, [50] a standard supported by evi-
dence that high-volume readers (more than 5,000 mam-
mograms per year) showed a significantly higher
sensitivity than those reading fewer than 3,600 per year.
[51] This was achieved without referring more women out
for unnecessarytests. Within programs, there is high-vol-
ume screening, and evaluation of outcomes is carried out
routinely.
Unfortunately, in most provinces and territories, the
majority of women do not receive screening through such
organized programs [48] (Figure 4), and much of the
screening mammography in the country does not report
on quality outcomes. Outside of programs, the minimum
number of mammograms required to achieve accredita-
tion is only 480 per year, which is well below the number
recommended for high-quality screening. This is a policy
issue that will need to be resolved if we are to maximize
the gains from screening mammography.
Another measure of quality is the time between screening
and diagnosis. Recent studies have shown average delays
of about 3.7 weeks from screening to diagnosis in Canada,
increasing to 6.9 weeks if a biopsy is involved. [52] Within
the programs, goals have been set to minimize this delay.
There are still differences in the ability of organized pro-
grams to reach some women for screening. The Canadian
population health survey of 1996–1997 showed that only
29% of Newfoundland and Labrador women aged 50 to
69 reported undergoing screening mammography in the
previous two years, as compared with 59% in Ontario and
60% in New Brunswick [51] (Figure 5). Mammography
use is directly related to education and income, with less
mammography being reported by women with less than a
high school education and/or lower income. [53]
Treatment
Regional or provincial variations in treatment practices
and access to radiotherapy have been found. [54,55] It is
hoped that clinical practice guidelines, developed as part
of the national breast screening initiative, [56] will ensure
that common treatment standards are in place across the
country. There is also a need to ensure that guidelines,
once available, are translated into practice.
Discussion
Data Limitations
The data presented represent high-quality population-
based data available from a number of sources. However,
surveillance in Canada could be enhanced by various ini-
tiatives. First, there is no readily available data on the stag-
ing of cancer across the country, as stage is not routinely
collected by cancer registries; this would be valuable in
interpreting whether there are differences in time or place
in the diagnosis or stage-specific survival of breast cancer.
Further, there is no specific information on Aboriginal or
other groups, as ethnic origin is not collected on Canadian
registries. Finally, while the National Population Health
Survey and the Canadian Community Health Survey
provide excellent self-report data on screening, enhanced
data from actual screening providers in addition to those
Proportion of Women Aged 50–69 Who Participated in Pro- vincial Breast Cancer Screening Programs in 1997 and 1998 Figure 4
Proportion of Women Aged 50–69 Who Participated 
in Provincial Breast Cancer Screening Programs in 
1997 and 1998 Source: Public Works and government 
Services Canada, 2001. Cat. No. H1-9/13-1998. ISBN 0-662-
65807-8
Proportion of Women Aged 50 to 69 Reporting Having Had  a Screening Mammogram Within the Last Two Years, 1996– 97 Figure 5
Proportion of Women Aged 50 to 69 Reporting Hav-
ing Had a Screening Mammogram Within the Last 
Two Years, 1996–97 Source: Statistics Canada. National 
Population Health Survey, 1996–1997BMC Women's Health 2004, 4:S12 http://www.biomedcentral.com/1472-6874/4/S1/S12
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currently reporting from the screening programs would
allow us to get more accurate data on screening prevalence
and outcomes across the country.
Recommendations
Policy Implications and Recommendations
There are several areas, particularly in screening, in which
the guidelines are unclear and there is a need to develop
ways to involve women fully in informed decision mak-
ing. Several policy issues need to be addressed to prevent
disparities in access to high-quality services:
• The patenting issues of genetic tests and thus the availa-
bility of testing for women with high-risk histories need to
be clarified.
• There should be leadership to ensure that all screening
occurs in the context of high-quality, coordinated
programs.
• The key components of organized screening programs,
identified well over a decade ago, should be put in place.
• When clinical guidelines are known, there is a require-
ment for health services research or ongoing monitoring
by the provincial cancer agencies to assess the adherence
levels to guidelines and to ensure equity of access within
provinces.
If attention is paid to these issues, we have some hope of
minimizing the rates of breast cancer in Canada and fur-
ther reducing the burden for the over 20,000 women who
will develop breast cancer in Canada this year.
Note
The views expressed in this report do not necessarily rep-
resent the views of the Canadian Population Health Initi-
ative, the Canadian Institute for Health Information or
Health Canada.
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